Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial) | MicrobiomeTrials
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-11-25Est. Completion: 2030-04-30
Enrollment target: 1,703 participants
Locations
University Clinical Hospital in Bialystok, Bialystok, Poland
Nicolaus Copernicus University Ludwik Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
Medical University of Gdansk, Gdansk, Poland
Regional Specialist Hospital in Grudziadz, Grudziądz, Poland
Upper-Silesian Heart Center, Katowice, Poland
John Paul II Hospital, Krakow, Poland
Medical University of Lodz, Lodz, Poland
Zbigniew Religa Heart Center "Medinet", Nowa Sól, Poland
Provincial Specialist Hospital in Olsztyn, Olsztyn, Poland
Institute of Medical Sciences in Opole, Opole, Poland
J. Struś Hospital, Poznan, Poland
Poznan University of Medical Sciences, Poznan, Poland
Pomeranian Medical University, Szczecin, Poland
Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland
Medicover Hospital, Warsaw, Poland
Wroclaw Medical University, Wroclaw, Poland
Zbigniew Religa Heart Center "Medinet", Wroclaw, Poland
Other microbiome trials you might be interested in